Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)HS Rugo, SM Tolaney, MN Dickler et al.|Cancer Research|2018Cited by 16